Inolitazone

• Description :

  Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.

• Product Name Alternative :

  Efatutazone; CS-7017; RS5444

• UNSPSC :

  12352005

• Target :

  PPAR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/inolitazone.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N1)SC(CC2=CC=C(OCC3=NC4=CC=C(OC5=CC(C)=C(N)C(C)=C5)C=C4N3C)C=C2)C1=O

• Molecular Formula :

  C27H26N4O4S

• Molecular Weight :

  502.58

• References & Citations :

  [1]Copland JA, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13;25 (16) :2304-17.|[2]Marlow LA, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009 Feb 15;69 (4) :1536-44.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  PPARγ

• Citation 01 :

  Exp Cell Res. 2017 Dec 15;361 (2) :246-256. |Front Microbiol. 2019 Jan 8:9:3257.|bioRxiv. 2025 Oct 22.|Cancer Med. 2018 May;7 (5) :1955-1966. |Int J Oncol. 2018 Jun;52 (6) :1991-2000.

• CAS Number :

  [223132-37-4]